Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach

: Pulmonary drug delivery of ciprofloxacin hydrochloride offers effective local antibacterial activity and convenience of easy application. Spray drying is a trustworthy technique for the production of ciprofloxacin hydrochloride microparticles. Quality by design (QbD), an up-to-date regulatory-based quality management method, was used to predict the final quality of the product. According to the QbD-based theoretical preliminary parameter ranking and priority classification, dry powder inhalation formulation tests were successfully performed in practice. When focusing on the critical parameters, the practical development was more effective and was in correlation with our previous findings. Spray drying produced spherical microparticles. The dry powder formulations prepared were examined by particle size analysis, scanning electron microscopy, Fourier-transform infrared spectroscopy, X-ray powder diffraction, differential scanning calorimetry, and in vitro drug release and aerodynamic particle size analyses were also performed. These formulations showed an appropriate particle size ranging between 2 and 4 μ m and displayed an enhanced aerosol performance with fine particle fraction up to 80%.

[1]  B. Aksu,et al.  Quality by design case study 1: Design of 5-fluorouracil loaded lipid nanoparticles by the W/O/W double emulsion - Solvent evaporation method. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  Hidemichi Fujii,et al.  Decomposition analysis of green chemical technology inventions from 1971 to 2010 in Japan , 2016 .

[3]  Danforth P Miller,et al.  Formulation Design of Dry Powders for Inhalation. , 2015, Journal of pharmaceutical sciences.

[4]  H. Chan,et al.  Inhaled formulations and pulmonary drug delivery systems for respiratory infections. , 2015, Advanced drug delivery reviews.

[5]  K. Alzoubi,et al.  Ciprofloxacin-Induced Antibacterial Activity Is Attenuated by Phosphodiesterase Inhibitors , 2014, Current therapeutic research, clinical and experimental.

[6]  Ying Huang,et al.  Studies on the spray dried lactose as carrier for dry powder inhalation , 2014 .

[7]  Anne Marie Healy,et al.  Dry powders for oral inhalation free of lactose carrier particles. , 2014, Advanced drug delivery reviews.

[8]  P. Colombo,et al.  Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction. , 2014, International journal of pharmaceutics.

[9]  G. K. Raju,et al.  Understanding Pharmaceutical Quality by Design , 2014, The AAPS Journal.

[10]  H. Stass,et al.  Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. , 2013, Clinical therapeutics.

[11]  H. Chan,et al.  Inhaled antibiotics to treat lung infection. , 2013, Pharmaceutical patent analyst.

[12]  K. Amighi,et al.  New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. , 2013, Journal of pharmaceutical sciences.

[13]  H. Mansour,et al.  Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery , 2013, International journal of nanomedicine.

[14]  J. Zwischenberger,et al.  Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation , 2013, Drug design, development and therapy.

[15]  D. Touw,et al.  Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[16]  Jianfeng Chen,et al.  Preparation of microsized spherical aggregates of ultrafine ciprofloxacin particles for dry powder inhalation (DPI) , 2009 .

[17]  Y. Yeo,et al.  Development of highly porous large PLGA microparticles for pulmonary drug delivery. , 2009, Biomaterials.

[18]  Nazrul Islam,et al.  Dry powder inhalers (DPIs)--a review of device reliability and innovation. , 2008, International journal of pharmaceutics.

[19]  B. Pulliam,et al.  Nanoparticles for drug delivery to the lungs. , 2007, Trends in biotechnology.

[20]  K. Kisich,et al.  The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. , 2005, American Journal of Respiratory and Critical Care Medicine.

[21]  P. Anderson History of aerosol therapy: liquid nebulization to MDIs to DPIs. , 2005, Respiratory care.

[22]  F. Fawaz Ciproflexacin-loaded polyisobutylcyanoacrylate nanoparticles: Preparation and characterization , 1997 .

[23]  R. Ambrus,et al.  Development of dry powder carrier systems for pulmonary application , 2015 .

[24]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride. , 2011, Journal of pharmaceutical sciences.

[25]  M. Dolovich,et al.  Labiris NR, Dolovich MB. Pulmonary drug delivery: part II. the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications , 2004 .